Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyOscar Health prenatal screening Coverage Update | …
    Ask Trek AI about this page
    CurrentOscar HealthPolicy N/A

    Prenatal Screening (Nongenetic)

    Customize your policy alerts

    Sign up for all Oscar Health policy alerts

    Know when Oscar Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage, indications, and limitations for routine nongenetic prenatal screening tests for pregnant individuals, and provides related clinical background and guideline references for providers and payers.

    Policy Summary
    PayerOscar Health
    PolicyPrenatal Screening (Nongenetic)
    Policy CodePolicy N/A
    Change TypeEditorial — no material clinical change
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionDocument and code routine prenatal screening tests and confirm prior-authorization requirements for bundled obstetric panels when required by the payer.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ~15routine prenatal screening items listed as meeting criteria
    36-37 wksGroup B strep screening timing
    24-28 wksRh(D) antibody repeat timing
    >=50CPT/HCPCS procedure codes referenced

    Coverage Criteria for Prenatal Nongenetic Screening

    Routine prenatal screening (meets criteria)

    Covered when the following routine prenatal screenings are performed for pregnant individuals:

    Routine prenatal screening list: Antigen/antibody combination assay screening for HIV; Screening for Chlamydia trachomatis; Screening for Neisseria gonorrhoeae; Triple panel screening for hepatitis B (HBsAg, anti-HBs, total anti-HBc); Syphilis screening; Hepatitis C antibody screening; Screening for type 2 diabetes at the first prenatal visit; Screening for gestational diabetes during gestational weeks 24–28 and at the first prenatal visit if risk factors are present; Determination of blood type, Rh(D) status, and antibody status at the first prenatal visit with repeat Rh(D) antibody testing at 24–28 weeks for all unsensitized Rh(D)-negative individuals unless the biological father is known to be Rh(D)-negative; Screening for anemia with CBC or hemoglobin/hematocrit with MCV; Group B streptococcal screening once per pregnancy (recommended at 36–37 weeks); Urinalysis and urine culture; Rubella antibody testing; Testing for varicella immunity

    Listed as meeting criteria in document

    Additional covered indications

    Additional covered situations:

    Age- or risk-based repeat screening: For pregnant individuals <25 years of age or those at continued high risk of infection (e.g., new or multiple sex partners, history of STIs, past or current injection drug use), third trimester re-screening of Chlamydia trachomatis, Neisseria gonorrhoeae, syphilis, and/or HIV meets criteria.third trimester

    Document specifies age- and risk-based third trimester re-screening

    Fetal fibronectin for preterm labor symptoms: For individuals with singleton or twin pregnancies presenting in the ambulatory setting with signs or symptoms of preterm labor, fetal fibronectin (FFN) assay meets criteria.clinical presentation of preterm labor

    VA/DoD and document support FFN use between ~24 and 34 6/7 weeks when results may affect management

    TB screening for high-risk individuals: Screening for tuberculosis in pregnant individuals deemed to be at high risk for TB meets criteria.risk-based assessment

    Listed among additional covered indications

    Not medically necessary for routine use

    Not covered routine test: Human chorionic gonadotropin (hCG) hormone testing for individuals with a normal, uncomplicated pregnancy does not meet criteria.

    Document explicitly states hCG testing does not meet criteria for uncomplicated pregnancies

    Covered screening criteria

    Covered when consistent with cited guideline recommendations and medical necessity:

    Routine universal infectious screening: Screen all pregnant individuals early in pregnancy for syphilis, HIV, hepatitis B (HBsAg) and hepatitis C; use a laboratory-based antigen/antibody (Ag/Ab) HIV assay as the first test unless rapid point-of-care testing is required for follow-up concerns.first prenatal visit

    CDC and VA/DoD recommend universal early pregnancy testing for these infections

    Risk-based repeat testing: Repeat testing in the third trimester should be performed for individuals at increased risk (for example age <25, new/multiple partners, high-local prevalence, substance use); consider HIV retesting in the third trimester, preferably at <36 weeks for those at high risk or in high-incidence settings.third trimester (preferably <36 weeks for HIV retest)

    CDC guidance recommends third-trimester repeat testing for high-risk individuals

    Gestational diabetes screening:

    Human chorionic gonadotropin (hCG) hormone testing for individuals with a normal, uncomplicated pregnancy does not meet criteria and is considered not medically necessary when performed as routine prenatal screening in the absence of complications or specific clinical indications.

    Routine screening for bacterial vaginosis (BV), Trichomonas vaginalis, and routine HSV‑2 serologic screening among asymptomatic pregnant individuals is not supported by the evidence and is not recommended as part of routine prenatal screening; symptomatic individuals should be evaluated and treated per clinical guidance.

    Procedure and billing codes listed in this Medical Policy are provided as a general reference to indicate commonly used CPT/HCPCS codes relevant to prenatal nongenetic screening; these lists may not be exhaustive and providers should confirm correct and complete code selection when submitting claims or requesting authorization.

    As noted elsewhere in this Policy, hCG testing in normal, uncomplicated pregnancies is explicitly listed as not meeting criteria and therefore is not covered when ordered solely for routine prenatal screening without clinical indication.

    To reiterate, routine testing for BV, Trichomonas vaginalis, and routine serologic screening for HSV‑2 in asymptomatic pregnant individuals is not recommended as standard prenatal screening; testing should be targeted to symptomatic patients or those with specific risk factors.

    Coding and Procedure Codes

    Obstetric panels and urinalysisCPTCovered
    80055Obstetric panel (includes specified CBC, HBsAg, rubella Ab, syphilis non-treponemal, RBC antibody screen, ABO and Rh typing); panel must include listed components
    80081Obstetric panel (includes HIV testing) with specified components including CBC, HBsAg, HIV Ag/Ab (87389), rubella Ab, syphilis non-treponemal, RBC antibody screen, ABO and Rh typing, and urinalysis components
    81001Urinalysis by dip stick or tablet reagent with automated microscopy
    Urinalysis, glucose, and related maternity lab codesCPTCovered
    81002Urinalysis by dip stick or tablet reagent; non-automated without microscopy
    81003Urinalysis by dip stick or tablet reagent; automated without microscopy
    81007Urinalysis; bacteriuria screen, except by culture or dipstick
    81015Urinalysis; microscopic only
    82677Estriol
    82731Fetal fibronectin, cervicovaginal secretions, semi-quantitative
    82947Glucose; quantitative, blood
    82950Glucose; post glucose dose (includes glucose)
    82951Glucose tolerance test (GTT), 3 specimens (includes glucose)
    82962Glucose, blood by glucose monitoring device(s) cleared by the FDA specifically for home use
    1–10 of 11
    1/2
    hCG and CBC codesCPTCovered
    84702hCG; quantitative
    84703hCG; qualitative
    84704hCG; free beta chain
    85004Blood count; automated differential WBC count
    85007Blood count; blood smear, microscopic exam with manual differential WBC count
    85009Blood count; manual differential WBC count, buffy coat
    85014Hematocrit
    85018Hemoglobin
    85025CBC, automated and automated differential
    85027CBC, automated
    Infectious disease serology and related testsCPTCovered
    86480Tuberculosis test, cell mediated immunity antigen response measurement; gamma interferon
    86580Skin test; tuberculosis, intradermal
    86592Syphilis test, non-treponemal antibody; qualitative (e.g., VDRL, RPR, ART)
    86593Syphilis test, non-treponemal antibody; quantitative
    86631Antibody; Chlamydia
    86632Antibody; Chlamydia, IgM
    86704Hepatitis B core antibody (HBcAb); total
    86706Hepatitis B surface antibody (HBsAb)
    86762Antibody; rubella
    86780Antibody; Treponema pallidum
    1–10 of 16
    1/2
    Microbiology and culture codesCPTCovered
    87077Culture, bacterial; aerobic isolate, additional methods required for definitive identification, each isolate
    87081Culture, presumptive, pathogenic organisms, screening only
    87086Culture, bacterial; quantitative colony count, urine
    87088Culture, bacterial; with isolation and presumptive identification of each isolate, urine
    87110Culture, chlamydia, any source
    87270Infectious agent antigen detection by immunofluorescent technique; Chlamydia trachomatis
    87320Infectious agent antigen detection by immunoassay; Chlamydia trachomatis
    87340Hepatitis B surface antigen (HBsAg)
    Covered CPT Codes (partial list — section VII)CPTCovered
    84704Gonadotropin, chorionic (hCG); free beta chain.
    85004Blood count; automated differential WBC count.
    85007Blood count; blood smear, microscopic examination with manual differential WBC count.
    85009Blood count; manual differential WBC count, buffy coat.
    85014Blood count; hematocrit (Hct).
    85018Blood count; hemoglobin (Hgb).
    85025Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count).
    85027Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count).
    85032Blood count; manual cell count (erythrocyte, leukocyte, or platelet) each.
    85041Blood count; red blood cell (RBC), automated.
    1–10 of 15
    1/2
    Covered CPT Codes (continued)CPTCovered
    86632Antibody; Chlamydia, IgM.
    86704Hepatitis B core antibody (HBcAb); total.
    86706Hepatitis B surface antibody (HBsAb).
    86762Antibody; rubella.
    86780Antibody; Treponema pallidum.
    86787Antibody; varicella-zoster.
    86803Hepatitis C antibody.
    86804Hepatitis C antibody; confirmatory test (e.g., immunoblot).
    86850Antibody screen, RBC, each serum technique.
    86900Blood typing, serologic; ABO.
    1–10 of 16
    1/2
    Covered infectious agent detection CPT CodesCPTCovered
    87270Infectious agent antigen detection by immunofluorescent technique; Chlamydia trachomatis.
    87320Infectious agent antigen detection by immunoassay technique; Chlamydia trachomatis (EIA/ELISA/IMCA) qualitative or semiquantitative.
    87340Infectious agent antigen detection by immunoassay technique; hepatitis B surface antigen (HBsAg).
    87341Infectious agent antigen detection by immunoassay technique; hepatitis B surface antigen (HBsAg) neutralization.
    87491Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, direct probe technique.
    87494Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique.
    87590Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis and Neisseria gonorrhoeae, multiplex amplified probe technique.
    87591Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, direct probe technique.
    87653Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique.
    87800Infectious agent detection by nucleic acid (DNA or RNA); Streptococcus, group B, amplified probe technique.
    1–10 of 13
    1/2
    Covered HCPCS/G CodesHCPCSCovered
    G0306Complete CBC, automated (HgB, HCT, RBC, WBC, without platelet count) and automated WBC differential count.
    G0307Complete (CBC), automated (HgB, HCT, RBC, WBC; without platelet count).
    G0472Hepatitis C antibody screening, for individual at high risk and other covered indication(s).
    Fetal fibronectin thresholds
    Low threshold<10 ng/mL (examples show under 10% delivered before 34 weeks)
    High threshold>200 ng/mL (examples show 37–67% delivered before 34 weeks)
    Negative predictive value99.5% within 7 days; 99.2% within 14 days
    Third-trimester HIV retesting threshold
    Who to retestRetest in the third trimester for individuals at increased risk for acquiring HIV (e.g., substance use, new/multiple partners, partners with HIV, or residing in high-prevalence areas)

    Provider Actions, Authorization, and Documentation

    Prior Authorization

    Authorization and medical necessity

    Services must meet authorization and medical necessity guidelines for the procedure, diagnosis, and the member's state of residence; coverage does not guarantee reimbursement.

    • Ensure requested prenatal nongenetic screening is supported by documented medical necessity before submission.
    Prior Authorization

    Check PA for obstetric panels

    Certain bundled obstetric panel CPT/HCPCS codes (for example, 80055 and 80081) and specified urinalysis codes are listed among applicable procedure codes — check the payer's prior‑authorization requirements for these panels before ordering.

    • Verify whether prior authorization is required for obstetric panels (80055, 80081) and associated urinalysis codes (e.g., 81001) prior to performing the panel.

    Background and Rationale

    Prenatal nongenetic screening is intended to assess maternal and fetal health in asymptomatic pregnant individuals to identify conditions that may affect the pregnancy. Routine laboratory screening commonly includes tests for anemia, blood type and antibodies (including Rh and antibody status), infectious diseases (for example, HIV, syphilis, hepatitis B and C, chlamydia, and gonorrhea), Group B streptococcus screening, and glucose testing for preexisting diabetes or gestational diabetes. The goal of these screenings is early detection to guide prevention, counseling, and treatment when indicated.

    Definitions and Abbreviations

    FFN — fetal fibronectin definition
    DefinitionFetal fibronectin (FFN) is a protein produced during pregnancy located at the decidual–chorionic interface; its presence in cervicovaginal secretions indicates disruption of that interface
    Clinical useMeasured in cervicovaginal secretions to help predict spontaneous preterm birth in singleton and twin gestations
    MechanismReleased into cervicovaginal secretions when the decidual–chorionic interface is disrupted; described as the 'glue' holding the amniotic sac to the uterine lining
    GBS — Group B streptococcal disease definition
    DefinitionGroup B streptococcal disease (GBS) denotes maternal bacterial colonization screened antepartum to guide intrapartum antibiotic prophylaxis
    Screening purpose
    Policy Summary
    PayerOscar Health
    PolicyPrenatal Screening (Nongenetic)
    Policy CodePolicy N/A
    Change TypeEditorial — no material clinical change
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionDocument and code routine prenatal screening tests and confirm prior-authorization requirements for bundled obstetric panels when required by the payer.
    SourceLink
    On This Page
    Coverage Criteria for Prenatal Nongenetic ScreeningCoding and Procedure CodesProvider Actions, Authorization, and DocumentationBackground and RationaleDefinitions and Abbreviations
    Screen for gestational diabetes after 24 weeks (preferably 24–28 weeks); screen for preexisting type 2 diabetes at the first prenatal visit when risk factors are present.
    >=24 weeks for GDM; first prenatal visit for preexisting diabetes screening if risk factors

    Aligned with ADA and other guideline recommendations cited in the document

    Timing guidanceA second test during the third trimester, preferably at <36 weeks' gestation, should be considered for those at high risk
    Incidence threshold to consider retestingConsider retesting when HIV incidence in the clinical setting is ≥1 per 1,000 individuals screened per year
    HCV screening exception prevalence threshold
    Routine recommendationScreen for hepatitis C during each pregnancy
    Exception thresholdExcept in settings where HCV prevalence is <0.1%
    Source guidanceCDC recommendation for universal pregnancy screening with a prevalence-based exception
    Billing Rule

    Applicable procedure codes for authorization and claims

    Reference the policy's listed CPT and HCPCS procedure codes when seeking authorization or submitting claims for prenatal nongenetic screening; use the codes applicable to the tests performed.

    • Use the listed CPT/HCPCS codes (see policy sections VII, e.g., 84704, 85004, 86592, 87340, G0306, G0472) when requesting authorization and filing claims.
    • Confirm code selection matches the exact test performed (panel vs individual assay).
    Billing Rule

    Verify code support for submitted services

    When in doubt about whether a specific code is supported by this policy, refer to the full procedure code list in Section VII and the policy text; confirm correct code(s) on the claim to reflect the exact service provided.

    • Procedure codes in the policy are a reference and may not be exhaustive — ensure correct code selection for the submitted laboratory or screening service.
    Note
    Note
    Documentation Required

    Provider documentation responsibility

    Providers are responsible for submission of accurate documentation of services performed and must code claims according to standard coding guidelines; failure to submit accurate documentation may result in denial or recoupment.

    • Include documentation of indication, test performed, and the member's state of residence when submitting authorization requests and claims.
    Documentation Required

    Document first-visit screening

    Document screening tests performed at the first prenatal visit (offer and record tests such as HBsAg, syphilis, HIV, hepatitis C, CBC, ABO/Rh blood typing and antibody screen, rubella and varicella IgG, urinalysis and culture) to support coverage determinations.

    • Record which first‑visit labs were offered and performed to support medical necessity for those services.
    Billing Rule

    Procedure codes reference reminder

    Procedure codes provided in Section VII are intended as a reference; before submitting laboratory claims ensure you select the correct code(s) that match the specific test or panel performed.

    • Confirm whether the service was billed as an obstetric panel (e.g., 80055, 80081) or as individual component CPT/HCPCS codes and submit accordingly.
    Denial Risk

    Coding and documentation compliance — denial risk

    Claims may be denied or recouped if industry standard coding/billing guidelines or current reimbursement policies are not followed and accurate documentation is not submitted.

    • Ensure coding aligns with the tests performed and documentation supports medical necessity to avoid denials or repayment requests.
    Denial Risk

    Government policy precedence — check LCD/NCD/Medicaid

    If a federal or state government coverage determination (for example, LCDs/NCDs or state Medicaid policy) conflicts with this policy for a given member, the government policy will be used to make the coverage determination.

    • Check applicable Medicare/Medicaid LCDs or NCDs and state Medicaid guidance for members covered by those programs prior to relying solely on this policy.
    Note

    Procedure codes are non-exhaustive — confirm code selection

    Procedure codes appearing in Medical Policy documents are included only as a general reference tool and may not be all‑inclusive; confirm that submitted codes are supported by the documentation and policy.

    • If a submitted code is not listed in the policy, provide documentation tying the billed code to the performed service and medical necessity.
    Detects maternal colonization to prevent early-onset neonatal GBS disease via intrapartum prophylaxis
    Timing noteTypically screened once per pregnancy (recommended at 36–37 weeks) to inform intrapartum management
    Preconception counseling and glycemic target
    Preconception counseling recommendationADA: incorporate preconception counseling into routine diabetes care for people with diabetes and reproductive potential
    A1C targetAim for A1C <6.5% (48 mmol/mol) when safely possible to reduce pregnancy complications
    Care modelIndividuals with preexisting diabetes planning pregnancy should ideally receive multidisciplinary preconception care (endocrinologist, MFM, RDN, diabetes educator)
    Prenatal nongenetic screening — definition
    DefinitionPrenatal nongenetic screening comprises screening tests during pregnancy to assess maternal and fetal health that do not include genetic or chromosomal diagnostic testing
    Included testsExamples include infectious disease testing, blood counts, blood typing, urinalysis, and biomarkers referenced in guideline literature
    PurposeIdentify conditions that may affect pregnancy to enable prevention or treatment without involving genetic/chromosomal diagnostics